A Randomized, Double-blind, Dose-finding Study to Evaluate the Change in Weight After 24 Weeks Treatment With 8 Doses of LIK066 Compared to Placebo in Obese or Overweight Adults, Followed by 24 Weeks Treatment With 2 Doses of LIK066 and Placebo
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Nov 2017
At a glance
- Drugs LIK 066 (Primary)
- Indications Obesity; Overweight
- Focus Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 07 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 29 Sep 2017 Planned primary completion date changed from 27 Aug 2018 to 6 Feb 2018.
- 15 May 2017 Status changed from not yet recruiting to recruiting.